Alvogen Pumping $250M into Developing Biosimilars, with New Iceland Plant

05-12-2013 Genetic Engineering NewsComments (0)


Alvotech said today it will spend $250 million toward developing and manufacturing a portfolio of biosimilar monoclonal antibodies, expanding a portfolio of biosimilar mAb molecules the company plans to bring to market by 2018. That investment includes ...

Read more on Genetic Engineering News

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top